DEC 31, 2015 9:08 AM PST

World's First Dengue Fever Vaccine Approved in 3 Countries

WRITTEN BY: Xuan Pham
Dengue fever is a mosquito-borne disease that’s prevalent in tropical locations like Latin America, Southeast Asia, and the Pacific islands. Up until now there was no vaccine against the dengue virus. But the first ever developed vaccine has swiftly gotten approval in three countries, with more approvals expected soon.
Mosquito-borne disease affecting millions has had no approved vaccine until now
The vaccine against the dengue virus, Dengvaxia, was developed and is manufactured by the French pharmaceutical giant Sanofi.
 
"It's a major step in the prevention of dengue and for public health," Olivier Charmeil, head of Sanofi's vaccines division, said in a statement.
 
Dengue fever is caused by any one of four related dengue virus that’s transmitted through mosquito bites. Once infected sufferers experience painful flu-like symptoms that, in severe cases, have the potential to cause life-threatening dengue hemorrhagic fever or dengue shock syndrome. The Centers for Disease Control and Prevention estimates that as many as 400 million people are infected yearly; about 22,000 people die from it.
 

 
The Dengvaxia vaccine is actually based on an attenuated form of the yellow fever virus. This is because both viruses are very similar, sharing the same Genus. Geneticists then tweaked the yellow fever virus version to make it express the four types of dengue proteins. Once immunized with this modified virus, the host should be able to make antibodies against all four forms of dengues. Reportedly, Sanofi's research and development on the Dengvaxia vaccine took 2 decades and cost in excess of $1.6 billion.
 
Mexico was the first to approve the vaccine on December 11, 2015. Then last week on December 22, 2015 Philippines became the first Asian country to approve the vaccine. Dengvaxia recently secured the green light in another country: Brazil, where over 1.4 million cases of dengue fever were reported in 2015 alone. The vaccine is currently being reviewed in about 20 other countries in Asia and Latin America.

The United States had it’s own scare with Dengue fever earlier this year when cases appeared in Hawaii and Florida. In Puerto Rico the disease is already considered endemic.
 
Dengvaxia is a not a flawless vaccine. Clinical trials show that it works to prevent the disease in about 60% of cases; this means that the vaccine has a one third chance of being ineffective. Furthermore, the efficacy of the vaccine is restricted to people between 9 to 45 years old. This excludes young children and the elderly, arguably the populations most at risk who need a dengue vaccine the most. But an imperfect vaccine may be better than no vaccine at all.

Sources: Scientific American, Yahoo News
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 11, 2020
Clinical & Molecular DX
Supervillain Alert! New Tech IDs Drug-Resistant Superbugs.
AUG 11, 2020
Supervillain Alert! New Tech IDs Drug-Resistant Superbugs.
The human body is made up of around 10 trillion cells. Fascinatingly, we have 10 times more bacterial cells on our bodie ...
SEP 07, 2020
Cancer
Identifying Robust Tumor Features for Better Radiomics
SEP 07, 2020
Identifying Robust Tumor Features for Better Radiomics
With the advancement of technology comes the renovation of classical medical techniques. Diagnostic is one of the areas ...
OCT 24, 2020
Clinical & Molecular DX
Software Flags Elevated Cerebral Palsy Risk in Premies
OCT 24, 2020
Software Flags Elevated Cerebral Palsy Risk in Premies
Diagnostic imaging scientists have developed a software tool for predicting the future onset of cerebral palsy in babies ...
NOV 07, 2020
Neuroscience
Device Measures Stress Hormones with Earwax
NOV 07, 2020
Device Measures Stress Hormones with Earwax
Researchers from University College London and King’s College London in the UK have developed a device that can me ...
NOV 16, 2020
Microbiology
Using the Microbiome to Diagnose or Treat Autism
NOV 16, 2020
Using the Microbiome to Diagnose or Treat Autism
Autism is a complex disorder that has sent researchers searching for what is causing it, as the rates continue to rise. ...
NOV 26, 2020
Clinical & Molecular DX
Routine Diagnostic Tests Linked to a 59 Percent Increase in Testicular Cancer Risk
NOV 26, 2020
Routine Diagnostic Tests Linked to a 59 Percent Increase in Testicular Cancer Risk
New research has revealed that exposure to radiation from diagnostic procedures such as X-rays could contribute to an el ...
Loading Comments...